Novel <i>BCR-ABL1</i> tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia.

Malik S., Hassan S., Eşkazan A. E.

Expert review of hematology, cilt.14, sa.11, ss.975-978, 2021 (SCI-Expanded, Scopus)

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 14 Sayı: 11
  • Basım Tarihi: 2021
  • Doi Numarası: 10.1080/17474086.2021.1990034
  • Dergi Adı: Expert review of hematology
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Chemical Abstracts Core, EMBASE, MEDLINE
  • Sayfa Sayıları: ss.975-978
  • Anahtar Kelimeler: Asciminib, chronic myeloid leukemia, flumatinib, HQP1351, K0706, novel therapies, olverembatinib, PF-114, tyrosine kinase inhibitor, vodobatinib, ASCIMINIB, THERAPY
  • İstanbul Üniversitesi-Cerrahpaşa Adresli: Evet